Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

• Status: Recruiting
• Trial end date: 2036-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emily Marcinkowski
• Treatments: Anastrozole; Exemestane; Letrozole; Tamoxifen

Criteria

Inclusion Criteria:

• Pathologically confirmed invasive breast cancer, clinically stage I-II.

• Clinically lymph node negative

• Eligible for anti-endocrine treatment (per medical oncologist)

• Postmenopausal women

• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Progesterone receptor negativity

• High grade tumor

• Synchronous non-breast malignancy

• Receiving any other investigational agents that could impact the efficacy of this trial regimen

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Anastrozole, Letrozole, Exemestane, Tamoxifen or other agents used in study

• Uncontrolled intercurrent illness

• Medical, psychiatric or other condition and/or social situations that would limit compliance with study requirements